JP7258748B2 - サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用 - Google Patents

サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用 Download PDF

Info

Publication number
JP7258748B2
JP7258748B2 JP2019527379A JP2019527379A JP7258748B2 JP 7258748 B2 JP7258748 B2 JP 7258748B2 JP 2019527379 A JP2019527379 A JP 2019527379A JP 2019527379 A JP2019527379 A JP 2019527379A JP 7258748 B2 JP7258748 B2 JP 7258748B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
alkynyl
alkenyl
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019527379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535749A5 (OSRAM
JP2019535749A (ja
Inventor
グレイ，ナタナエル，エス．
チャン，ティンフー
ジアン，バイシャン
クフャトコフスキ，ニコラス，ポール
Original Assignee
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド
Publication of JP2019535749A publication Critical patent/JP2019535749A/ja
Publication of JP2019535749A5 publication Critical patent/JP2019535749A5/ja
Application granted granted Critical
Publication of JP7258748B2 publication Critical patent/JP7258748B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019527379A 2016-11-22 2017-11-22 サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用 Active JP7258748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425519P 2016-11-22 2016-11-22
US62/425,519 2016-11-22
PCT/US2017/063132 WO2018098361A1 (en) 2016-11-22 2017-11-22 Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof

Publications (3)

Publication Number Publication Date
JP2019535749A JP2019535749A (ja) 2019-12-12
JP2019535749A5 JP2019535749A5 (OSRAM) 2021-01-14
JP7258748B2 true JP7258748B2 (ja) 2023-04-17

Family

ID=60703092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527379A Active JP7258748B2 (ja) 2016-11-22 2017-11-22 サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用

Country Status (6)

Country Link
US (2) US11306070B2 (OSRAM)
EP (1) EP3544971B1 (OSRAM)
JP (1) JP7258748B2 (OSRAM)
AU (1) AU2017363307B2 (OSRAM)
CA (1) CA3041563C (OSRAM)
WO (1) WO2018098361A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA3041563C (en) 2016-11-22 2023-10-31 Dana-Farber Cancer Institute, Inc. Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12)
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
KR20210040368A (ko) * 2018-06-29 2021-04-13 킨네이트 바이오파마 인크. 사이클린 의존성 키나제의 억제제
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CA3132387A1 (en) * 2019-04-23 2020-10-29 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
WO2020219926A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer with cdk inhibitors
WO2021087138A1 (en) * 2019-10-29 2021-05-06 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (cdk7)
CN111269217B (zh) * 2020-04-07 2021-01-08 苏州信诺维医药科技有限公司 一种嘧啶胺类化合物、其制备方法及应用
CN111393415B (zh) * 2020-04-30 2020-11-20 苏州信诺维医药科技有限公司 一种杂芳腈类化合物及其应用
CN114133394B (zh) * 2020-08-12 2023-12-08 赛诺哈勃药业（成都）有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
US20230303512A1 (en) * 2020-08-26 2023-09-28 Massachusetts Institute Of Technology Modulators of myb-mediated transcription and uses thereof
WO2023023534A2 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
EP4387609A4 (en) 2021-08-18 2025-07-02 Chemocentryx Inc ARYLSULFONYL (HYDROXY)PIPERIDINES AS CCR6 INHIBITORS
WO2023091726A1 (en) * 2021-11-18 2023-05-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin‑dependent kinase 12 (cdk12)
TW202329937A (zh) * 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114452391B (zh) * 2022-01-28 2023-08-25 深圳市泰尔康生物医药科技有限公司 Cdk16作为靶标在制备用于治疗三阴性乳腺癌的药物中的应用
JP7759145B2 (ja) 2023-03-09 2025-10-23 ミネアムリタ セラピューティクス， エルエルシー 胃癌の治療のための薬物の組み合わせ

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
JP2010536869A (ja) 2007-08-20 2010-12-02 ワイス・エルエルシー ナフチルピリミジン、ナフチルピラジンおよびナフチルピリダジン類似体、ならびにＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
JP2011515371A (ja) 2008-03-21 2011-05-19 ノバルティス アーゲー 新規ヘテロ環式化合物およびそれらの使用
JP2012511021A (ja) 2008-12-05 2012-05-17 アークル インコーポレイテッド Ｒａｆの阻害剤およびその使用
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015154038A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2016512534A (ja) 2013-03-13 2016-04-28 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピペリジン化合物及びこれらのオレキシン受容体調節因子としての使用
JP2016533379A (ja) 2013-10-18 2016-10-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
TR200500745T2 (tr) 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US8178672B2 (en) * 2004-10-19 2012-05-15 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase
KR100919343B1 (ko) 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
MX2011008444A (es) 2009-02-12 2011-09-06 Astellas Pharma Inc Derivado de heteroanillo.
US20110039873A1 (en) 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
KR20140009259A (ko) 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
EP3057954A2 (en) * 2013-10-18 2016-08-24 Syros Pharmaceuticals, Inc. Heteromaromatic compounds useful for the treatment of proliferative diseases
AU2016243529B2 (en) * 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CA3041563C (en) 2016-11-22 2023-10-31 Dana-Farber Cancer Institute, Inc. Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12)
US10969394B2 (en) 2016-11-28 2021-04-06 Dana-Farber Cancer Institute, Inc. Reagents and methods for analysis of proteins and metabolites targeted by covalent probes
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
AU2019395255B2 (en) * 2018-12-14 2025-02-27 Dana-Farber Cancer Institute, Inc. Pyrazolopyridine inhibitors of c-Jun-N-terminal kinases and uses thereof
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
AU2020414418A1 (en) * 2019-12-24 2022-07-21 Dana-Farber Cancer Institute, Inc. The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
JP2010536869A (ja) 2007-08-20 2010-12-02 ワイス・エルエルシー ナフチルピリミジン、ナフチルピラジンおよびナフチルピリダジン類似体、ならびにＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
JP2011515371A (ja) 2008-03-21 2011-05-19 ノバルティス アーゲー 新規ヘテロ環式化合物およびそれらの使用
JP2012511021A (ja) 2008-12-05 2012-05-17 アークル インコーポレイテッド Ｒａｆの阻害剤およびその使用
JP2016512534A (ja) 2013-03-13 2016-04-28 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピペリジン化合物及びこれらのオレキシン受容体調節因子としての使用
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
JP2016533379A (ja) 2013-10-18 2016-10-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
WO2015154038A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY（STN）［online］，2016年，CAS 登録番号：1998741-43-7 他

Also Published As

Publication number Publication date
US11306070B2 (en) 2022-04-19
WO2018098361A1 (en) 2018-05-31
AU2017363307B2 (en) 2021-07-29
CA3041563A1 (en) 2018-05-31
US20230227433A9 (en) 2023-07-20
CA3041563C (en) 2023-10-31
US20200361906A1 (en) 2020-11-19
JP2019535749A (ja) 2019-12-12
EP3544971B1 (en) 2022-07-06
EP3544971A1 (en) 2019-10-02
AU2017363307A1 (en) 2019-05-02
US11932625B2 (en) 2024-03-19
US20220213067A1 (en) 2022-07-07
US20210317105A9 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
JP6491202B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
JP7590185B2 (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
US12415816B2 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
JP2018522867A (ja) 縮合二環式ピリミジン誘導体およびこれらの使用
WO2020097400A1 (en) Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
EP3876930A1 (en) Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
JP2022541644A (ja) サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
AU2020301399B2 (en) HCK degraders and uses thereof
WO2023081141A1 (en) Thymidylate synthase inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230405

R150 Certificate of patent or registration of utility model

Ref document number: 7258748

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150